Sodium thiosulfate acts as a hydrogen sulfide mimetic to prevent intimal hyperplasia via inhibition of tubulin polymerisation

Diane Macabrey,a,b Alban Longchamp,a,b Michael R. MacArthur,c Martine Lambelet,a,b Severine Urfer,a,b
Sebastien Deglise,a,b,1 and Florent Allagnat*a,b,1*

aDepartment of Vascular Surgery, Lausanne University Hospital, Switzerland
bCHUV-Service de chirurgie vasculaire, Department of Biomedical Sciences, University of Lausanne, Bugnon 7A, Lausanne 1005, Switzerland
cDepartment of Health Sciences and Technology, Swiss Federal Institute of Technology (ETH) Zurich, Zurich, Switzerland

Summary

Background Intimal hyperplasia (IH) remains a major limitation in the long-term success of any type of revascularisation. IH is due to vascular smooth muscle cell (VSMC) dedifferentiation, proliferation, and migration. The gaseous transmitter Hydrogen Sulfide (H2S), mainly produced in blood vessels by the enzyme cystathionine-γ-lyase (CSE), inhibits IH in pre-clinical models. However, there is currently no H2S donor available to treat patients. Here we used sodium thiosulfate (STS), a clinically-approved source of sulfur, to limit IH.

Methods Low density lipoprotein receptor deleted (LDLR−/−), WT or Cse-deleted (Cse−/−) male mice randomly treated with 4 g/L STS in the water bottle were submitted to focal carotid artery stenosis to induce IH. Human vein segments were maintained in culture for 7 days to induce IH. Further in vitro studies were conducted in primary human vascular smooth muscle cells (VSMCs).

Findings STS inhibited IH in WT mice, as well as in LDLR−/− and Cse−/− mice, and in human vein segments. STS inhibited cell proliferation in the carotid artery wall and in human vein segments. STS increased polysulfides in vivo and protein persulfidation in vitro, which correlated with microtubule depolymerisation, cell cycle arrest and reduced VSMC migration and proliferation.

Interpretation STS, a drug used for the treatment of cyanide poisoning and calciphylaxis, protects against IH in a mouse model of arterial restenosis and in human vein segments. STS acts as an H2S donor to limit VSMC migration and proliferation via microtubule depolymerisation.

Funding This work was supported by the Swiss National Science Foundation (grant FN-310030_176158 to FA and SD and PZ00P3-185927 to AL); the Novartis Foundation to FA; and the Union des Sociétés Suisses des Maladies Vasculaires to SD, and the Fondation pour la recherche en chirurgie vasculaire et thoracique.

Copyright © 2022 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Keywords: Intimal hyperplasia; Smooth muscle cells; Proliferation; Hydrogen sulfide; Sodium thiosulfate
Research in context

Evidence before this study

Intimal hyperplasia (IH) is a complex process leading to vessel restenosis, a major complication following cardiovascular surgeries and angioplasties. Therapies to limit IH are currently limited. Pre-clinical studies suggest that hydrogen sulfide (H$_2$S), an endogenous gasotransmitter, limits restenosis. However, despite these potent cardiovascular benefits, H$_2$S-based therapeutics are not available. Sodium thiosulfate (Na$_2$S$_2$O$_3$) is a FDA-approved drug used for the treatment of cyanide poisoning and calciphylaxis, a rare condition of vascular calcification affecting patients with end-stage renal disease. Evidence suggest that thiosulfate may generate H$_2$S in vivo in pre-clinical studies.

Added value of this study

Here, we demonstrate that STS inhibits IH in a surgical mouse model and in human vein ex vivo. We further found that STS increases circulating polysulfide levels in vivo and inhibits IH via disruption of the normal cell’s cytoskeleton, leading to decreased cell proliferation and migration. Finally, STS rescues Cse knockout mice with impaired endogenous H$_2$S production from accelerated IH formation.

Implications of all the available evidence

These findings suggest that STS holds translational potentials to limit IH following vascular surgeries and should be investigated in clinical trials.

Introduction

Prevalence of peripheral arterial disease continues to rise worldwide, largely due to the combination of aging, smoking, hypertension, and diabetes mellitus.

Open or endo-vascular surgery remains the best treatment when daily life activities are compromised despite exercise therapy or in threatened limb. However, the vascular trauma associated with any vascular surgery eventually lead to secondary occlusion of the injured vessel. Re-occlusive lesions result in costly and complex recurrent end-organ ischemia, and often lead to loss of limb, brain function, or life. Despite the advent of new medical devices such as drug eluting stent (DES) and drug-coated balloons (DCB), restenosis has been delayed rather than suppressed, and stents still suffer from high rates of in-stent restenosis. Plus, the use of SES and DCB prolongs the need for anti-thrombotic therapies, with their associated risk of haemorrhages.

In December 2018, Katsanos and colleagues reported, in a systematic review and meta-analysis, an increased risk of all-cause mortality following application of paclitaxel—coated balloons and stents in the femoropopliteal artery. These findings were recently confirmed by other groups using the same data. However, other meta-analyses did not find any association between paclitaxel devices and long-term survival, despite similar target populations and vessel segments. Overall, these reports question the widespread use of paclitaxel for the treatment of restenosis, and supports the development of other approaches or use of other molecules. While the focal nature of restenotic lesions prompts the use of local treatment, systemic approaches for the treatment of restenosis still remains an option.

Restenosis is mainly due to intimal hyperplasia (IH), a process instated by endothelial cell injury and inflammation, which induces vascular smooth muscle cell (VSMC) reprogramming. VSMCs become proliferative and migrating, secrete extra-cellular matrix (ECM) and form a new layer called the neo-intima, which slowly reduces the vessel luminal diameter.

Hydrogen sulfide (H$_2$S) is a gasotransmitter derived from cysteine metabolism, produced endogenously through the transsulfuration pathway by 3 main enzymes, cystathionine-γ-lyase (CSE), cystathionine-β-synthase (CBS) and 3-mercaptopyruvate sulfurtransferase (3-MST). Mice lacking Cse develop more IH in after carotid ligation, and are rescued by H$_2$S supplementation. Circulating H$_2$S levels are reduced in humans suffering from vascular occlusive disease and pre-clinical studies using water-soluble sulfide salts such as Na$_2$S and NaHS have shown that H$_2$S has cardiovascular protective properties, including reduction of IH in vivo in rats, rabbits, mice, and ex-vivo in human vein segments. However, the fast and uncontrolled release, narrow therapeutic range and high salt concentration of these compounds limit their potential. Due to these limitations, H$_2$S-based therapy are currently not available.

Here, we focused on sodium thiosulfate (Na$_2$S$_2$O$_3$), a FDA-approved drug used in gram-quantity doses for the treatment of cyanide poisoning and calciphylaxis, a rare condition of vascular calcification affecting patients with end-stage renal disease. Pharmaceutical-grade sodium thiosulfate (STS) is available and thiosulfate has been suggested to release H$_2$S through non-enzymatic and enzymatic mechanisms.

We tested whether STS inhibits IH in a surgical mouse model and in an ex vivo model of IH in human vein culture. NaHS, a validated H$_2$S donor, was systematically compared to STS. We observed that STS was at least as potent as NaHS to inhibit IH in our two models. STS increased protein persulfidation and circulating polysulfide levels in vivo. STS inhibited apoptosis and matrix deposition associated with the development of IH, as well as VSMC proliferation and migration. We further observed that STS and NaHS induced microtubule depolymerisation in VSMCs, which may explain the anti-proliferative effect of STS in those cells.
Methods
For details on materials and reagents please see the Supplementary Table S1 and 2.

Mouse treatment
WT mice C57BL/6J (RRID:MGI:3752053) mice were purchased from Janvier Labs (Le Genest-Saint-Isle, France). LDL receptor knock out (LDLR<sup>-/-</sup>) mice (Ldlr<sup>tm1Her</sup>, JAX stock #002207; MGI Cat# 3611043, RRID:MGI:3611043), kindly provided by Prof. Caroline Pot (Lausanne university Hospital, Switzerland), were bred and housed in our animal facility and genotyped as previously described. All mice were housed at standard housing conditions (22 °C, 12 h light/dark cycle), with ad libitum access to water and regular diet, under 2.5 L of O<sub>2</sub> followed by PBS perfusion. Aortas, isoflurane anaesthesia (inhalation 2.5% isoflurane under 2.5 L of O<sub>2</sub>), changed every day. Mice were euthanized after 7 or 28 days of treatment by cervical dislocation under isoflurane anaesthesia (inhalation 2.5% isoflurane under 2.5 L of O<sub>2</sub>) followed by PBS perfusion. Aortas, carotid arteries, livers and serum or plasma (via intracarotid blood collection with a 24G needle) were harvested.

Cse<sup>-/-</sup> mice
Cse<sup>-/-</sup> mice were generated from a novel floxed line generated by embryonic injection of ES cells containing a Cse allele with LoxP sites flanking exon 2 (Cse<sup>tm1Habr</sup>, EUCOMM; RRID:IMSR: Cns110294). Both ES cells and recipient embryos were on C57BL/6J background. Mice that were homozygous for the floxed allele were crossed with CMV-cre global cre-expressing mice (B6.C-Tg(CMV-cre)1Cgn/J), which have been backcrossed with C57BL/6J for 10 generations to create constitutive whole-body Cse<sup>-/-</sup> animals on a C57BL/6J background. The线 was subsequently maintained by breeding animals heterozygous for the Cth null allele. Mouse ear biopsies were taken and digested in DirectPCR lysis reagent with proteinase K. WT, heterozygous and knockout mice were identified by PCR using the forward primer 5’-AGC ATG CTT AAT TTG TGC-3’ and reverse primer 5’-AGT CTG GGG TTG GAG GAA AAA-3’ to detect the WT allele and the forward primer 5’-TTC AAC ATC AGC CGC TAC AG-3’ to detect knock-out allele using the platinum DNA Polymerase.

Carotid artery stenosis (CAS) surgery
The carotid artery stenosis (CAS) was performed as previously published on 8 to 10 weeks old male WT or LDLR<sup>-/-</sup> mice. Treatment was initiated 3 days before surgery and continued for 28 days post-surgery until organ collection. The day of the surgery, mice were anaesthetised with an intraperitoneal injection of Ketamine (80 mg/kg) and Xylazine (15 mg/kg). The left carotid artery was exposed and separated from the jugular vein and vague nerve. Then, a 7.0 PERMA silk (Johnson & Johnson AG, Ethicon, Switzerland) thread was looped and tightened around the carotid in presence of a 35-gauge needle. The needle was removed, thereby restoring blood flow, albeit leaving a significant stenosis. The stenosis triggers IH proximal to the site of injury, which was measured 28 days post-surgery. Buprenorphine (0.05 mg/kg) was provided subcutaneously as post-operative analgesic every 12 h for 24 h. Mice were euthanized under isoflurane anaesthesia (inhalation 2.5% isoflurane under 2.5 L of O<sub>2</sub>) by cervical dislocation and exsanguination, perfused with PBS followed by buffered formalin 4% through the left ventricle. Surgeries were performed in a random order, alternating mice from different cages to minimise potential confounders such as the order of treatments and measurements, or animal/cage location. All series of surgeries included all the groups to be compared to minimise batch effects. Surgeons were blind to the group during surgeries.

Human tissue and VSMC culture
Static vein culture was performed as previously described. Briefly, the vein was cut in 5 mm segments randomly distributed between conditions. One segment (Do) was immediately preserved in formalin or flash frozen in liquid nitrogen and the others were maintained in culture for 7 days in RPMI-1640 Glutamax I supplemented with 10% FBS and 1% antibiotic solution (10,000 U/mL penicillin G, 10,000 U/mL streptomycin sulphate) in cell culture incubator at 37 °C, 5% CO<sub>2</sub> and 21% O<sub>2</sub>. Human VSMCs were also prepared from these human great saphenous vein segments as previously described. Vein explants were plated on the dry surface of a cell culture plate coated with 1% Gelatine type B (Sigma-Aldrich). Explants were maintained in RPMI, 10% FBS medium in a cell culture incubator at 37 °C, 5% CO<sub>2</sub>, 5% O<sub>2</sub>, random order. Treatment was initiated 3 days before surgery and continued for 28 days post-surgery until organ collection. The day of the surgery, mice were anaesthetised with an intraperitoneal injection of Ketamine (80 mg/kg) and Xylazine (15 mg/kg). The left carotid artery was exposed and separated from the jugular vein and vague nerve. Then, a 7.0 PERMA silk (Johnson & Johnson AG, Ethicon, Switzerland) thread was looped and tightened around the carotid in presence of a 35-gauge needle. The needle was removed, thereby restoring blood flow, albeit leaving a significant stenosis. The stenosis triggers IH proximal to the site of injury, which was measured 28 days post-surgery. Buprenorphine (0.05 mg/kg) was provided subcutaneously as post-operative analgesic every 12 h for 24 h. Mice were euthanized under isoflurane anaesthesia (inhalation 2.5% isoflurane under 2.5 L of O<sub>2</sub>) by cervical dislocation and exsanguination, perfused with PBS followed by buffered formalin 4% through the left ventricle. Surgeries were performed in a random order, alternating mice from different cages to minimise potential confounders such as the order of treatments and measurements, or animal/cage location. All series of surgeries included all the groups to be compared to minimise batch effects. Surgeons were blind to the group during surgeries.

Human VSMCs were also prepared from these human great saphenous vein segments as previously described. Vein explants were plated on the dry surface of a cell culture plate coated with 1% Gelatine type B (Sigma-Aldrich). Explants were maintained in RPMI, 10% FBS medium in a cell culture incubator at 37 °C, 5% CO<sub>2</sub>, 5% O<sub>2</sub>, random order. Treatment was initiated 3 days before surgery and continued for 28 days post-surgery until organ collection. The day of the surgery, mice were anaesthetised with an intraperitoneal injection of Ketamine (80 mg/kg) and Xylazine (15 mg/kg). The left carotid artery was exposed and separated from the jugular vein and vague nerve. Then, a 7.0 PERMA silk (Johnson & Johnson AG, Ethicon, Switzerland) thread was looped and tightened around the carotid in presence of a 35-gauge needle. The needle was removed, thereby restoring blood flow, albeit leaving a significant stenosis. The stenosis triggers IH proximal to the site of injury, which was measured 28 days post-surgery. Buprenorphine (0.05 mg/kg) was provided subcutaneously as post-operative analgesic every 12 h for 24 h. Mice were euthanized under isoflurane anaesthesia (inhalation 2.5% isoflurane under 2.5 L of O<sub>2</sub>) by cervical dislocation and exsanguination, perfused with PBS followed by buffered formalin 4% through the left ventricle. Surgeries were performed in a random order, alternating mice from different cages to minimise potential confounders such as the order of treatments and measurements, or animal/cage location. All series of surgeries included all the groups to be compared to minimise batch effects. Surgeons were blind to the group during surgeries.

Carotid and human vein histomorphometry
After 7 days in culture, or immediately upon vein collection (Do), the vein segments were fixed in buffered formalin, embedded in paraffin, cut into 5 μm sections, and stained using Van Gieson Elastic Laminae (VGE) as previously described. Three photographs per section were taken at 100x magnification and 8 measurements of the intima and media thicknesses were

www.thelancet.com Vol 78 Month April, 2022
made, evenly distributed along the length of the vein wall.

Left ligated carotids were isolated and paraffin-embedded. Six-µm sections of the ligated carotid artery were cut from the ligation towards the aortic arch and stained with VGEL for morphometric analysis. Cross sections at every 300 µm and up to 2 mm from the ligation were analysed using the Olympus Stream Start 2.3 software (Olympus, Switzerland). For intimal and medial thickness, 72 (12 measurements/cross section on six cross sections) measurements were performed, as previously described.31

Two independent researchers blind to the experimental groups did the morphometric measurements, using the Olympus Stream Start 2.3 software (Olympus, Switzerland).22

**H₂S and polysulfide measurement**

Free H₂S was measured in cells using the SF₇-AM fluorescent probe31 (Sigma-Aldrich). The probe was dissolved in anhydrous DMF at 5 mM and used at 5 µM in serum-free RPMI medium with or without VSMCs. Free polysulfide was measured in cells using the SSP₄ fluorescent probe. The probe was dissolved in DMF at 10 mM and diluted at 10 µM in serum-free RPMI medium with or without VSMCs. Fluorescence intensity (λex = 495 nm; λem = 520 nm) was measured continuously in a Synergy Mx fluorescent plate reader (BioTek Instruments AG, Switzerland) at 37 °C before and after addition of various donors, as indicated.

Plasma polysulfides were measured using the SSP₄ fluorescent probe. Plasma samples were diluted 3 times and incubated for 10 min at 37 °C in presence of 10 µM SSP₄. Plasma polysulfides were calculated using a Na₂S₃ standard curve. Liver polysulfides were measured using the SSP₄ fluorescent probe. Pulverized frozen liver was resuspended in PBS-0.5% triton X-100, sonicated and adjusted to 0.5 mg/ml protein concentration. Lysates were incubated for 30 min at 37 °C in presence of 10 µM SSP₄ and fluorescence intensity (λex = 495 nm; λem = 520 nm) was measured in a Synergy Mx fluorescent plate reader (BioTek Instruments AG, Switzerland).

**Persulfidation protocol**

Persulfidation protocol was performed using a dime-thione-based probe as recently described.32 Persulfidation staining was performed on VSMCs grown on glass coverslips. Briefly, 1 mM 4-Chloro-7-nitrobenzofurazan (NBF-Cl, Sigma) was diluted in PBS and added to live cells for 20 min. Cells were washed with PBS then fixed for 10 min in ice-cold methanol. Coverslips were rehydrated in PBS, and incubated with 1 mM NBF-Cl for 1 h at 37 °C. Daz2-Cy5.5 (prepared with 1 mM Daz-2, 1 mM alkyn Cy5.5, 2 mM copper(II)-TBTA, 4 mM ascorbic acid with overnight incubation at RT, followed by quenching for 1 h with 20 mM EDTA) was added to the coverslips and incubated at 37 °C for 1 h. After washing with methanol and PBS, coverslips were mounted in Vectashield mounting medium with DAPI and visualized with a 90i Nikon fluorescence microscope.

**BrdU assay**

VSMCs were grown at 80% confluence (5 × 10³ cells per well) on glass coverslips in a 24-well plate and starved overnight in serum-free medium. Then, VSMC were either treated or not (ctrl) with the drug of choice for 24 h in full medium (RPMI 10% FBS) in presence of 10 µM BrdU. All conditions were tested in parallel. All cells were fixed in ice-cold methanol 100% after 24 h of incubation and immunostained for BrdU. Images were acquired using a Nikon Eclipse 90i microscope. BrdU-positive nuclei and total DAPI-positive nuclei were automatically detected using the ImageJ software.22

**Flow cytometry**

VSMCs were grown at 70% confluence (5 × 10⁴ cells per well) and treated for 48 h with 15 mM STS or 10 nM Nocodazole. Then, cells were trypsinised, collected and washed in ice-cold PBS before fixation by dropwise addition of ice-cold 70% ethanol while slowly vortexing the cell pellet. Cells were fixed for 1 h at 4 °C, washed 3 times in ice-cold PBS and resuspended in PBS supplemented with 20 µg/mL RNase A and 10 µg/mL DAPI. Flow cytometry was performed in a Cytoflex-S apparatus (Beckmann).

**Wound healing assay**

VSMCs were grown at confluence (10⁴ cells per well) in a 12-well plate and starved overnight in serum-free medium. Then, a scratch wound was created using a sterile p200 pipette tip and medium was changed to serum-free RPMI 10% FBS. Repopulation of the wounded areas was recorded at t = 0 h and t = 10 h after the wound using the ImageJ software by two independent observers blind to the conditions. Data were calculated as a percentage of the wound closure.

**Immunohistochemistry**

Polychrome Herovici staining was performed on paraffin sections as described.33 Young collagen was stained blue, while mature collagen was pink. Cytoplasm was counterstained yellow. Haematoxylin was used to counterstain nuclei blue to black.

Collagen III staining was performed on frozen sections (OCT embedded) of human vein segments using...
mouse anti-Collagen III antibody. Briefly, tissue slides were permeabilised in PBS supplemented with 2 wt. % BSA and 0.1 vol. % Triton X-100 for 30 min, blocked in PBS supplemented with 2 wt. % BSA and 0.1 vol. % Tween-20 for another 30 min, and incubated overnight with the primary antibody diluted in the same buffer. The slides were then washed 3 times for 5 min in PBS supplemented with 0.1 vol. % Tween-20, and incubated for 1 h at room temperature with anti-mouse AlexaFluor 568 (1/1000, ThermoFischer). Slides were visualised using a Nikon 90i fluorescence microscope (Nikon AG). Collagen III immunostaining area was quantified using the ImageJ software and normalised to the total area of the vein segment.

PCNA (proliferating cell nuclear antigen), P4HA, cleaved caspase 3 and α-tubulin immunohistochemistry was performed on paraffin sections. After rehydration and antigen retrieval (TRIS-EDTA buffer, pH 9.17 min in a microwave at 500 W), immunostaining was performed on human vein or carotid sections using the Envision® Dual Link System-HRP (DAB+) according to manufacturer’s instructions. Slides were further counterstained with haematoxyl. PCNA and haematoxylin positive nuclei were manually counted by two independent observers blinded to the conditions.

α-tubulin immunofluorescent staining in human VSMCs was performed as previously described. Cell were fixed at -20 °C for 10 min in absolute methanol. Then, cells were blocked/permeabilised in PBS- triton 0.2%, BSA 3% for 45 min at room temperature. Cells were incubated overnight at 4 °C in the primary antibody diluted in PBS-0.1% tween, 3% BSA, washed 3 times in PBS and incubated for 1 h at room temperature with the secondary antibody diluted in PBS-0.1% tween, 3% BSA, washed again 3 times in PBS and mounted using Vectashield mounting medium for fluorescence with DAPI. The microtubule staining was quantified automatically using Fiji (ImageJ, 1.53c). Image processing was as follows: Plug-in, Tubeness/Process, Make Binary/Analyze, Skeletonize 2D/3D. Data were summarised as filament number and total length, normalised to the number of cells per images. Data were generated from images from 3 independent experiments, 3 to 4 images per experiment per condition.

Reverse transcription and quantitative polymerase chain reaction (RT-qPCR)
VSMCs were homogenised in Tripure Isolation Reagent (Roche, Switzerland), and total RNA was extracted according to the manufacturer’s instructions. RNA reverse transcription (Prime Script RT reagent, Takara), cDNA levels were measured by qPCR Fast SYBR® Green Master Mix in a Quant Studio 5 Real-Time PCR System (Applied Biosystems, ThermoFischer Scientific), using the following primers: Homo sapiens thiosulfate sulfurtransferase (TST), forward:5'-GCCTGGTGGATTCAAGGTCCTCA-3'; reverse: 5'-GACG GCACCCAGGATATGG-3'; Homo sapiens sulfite oxidase (SUOX), forward: 5'-GGTGCACTGTGGCC TATCA-3'; reverse: 5'-ACCCAGATCCCAGTCTCAGG-3'.

Western blotting
Mice aortas or human vein segments were flash-frozen in liquid nitrogen, ground to powder and resuspended in SDS lysis buffer (62.5 mM TRIS pH6,8, 5% SDS, 10 mM EDTA). Protein concentration was determined by DC protein assay. 10 to 20 μg of protein were loaded per well. Primary cells were washed once with ice-cold PBS and directly lysed with Laemmli buffer as previously described. Lysates were resolved by SDS-PAGE and transferred to a PVDF membrane Immobilon-P. Immunoblot analyses were performed as previously described using the antibodies described in supplementary Table S1. Membranes were revealed using Immunobilon Western Chemiluminescent HRP Substate in an Azure Biosystems 280, and analysed using Image J. Protein abundance was normalised to total protein using Pierce™ Reversible Protein Stain Kit for PVDF Membranes.

In vitro tubulin polymerization assay
The assay was performed using the In Vitro Tubulin Polymerization Assay Kit (≥99% Pure Bovine Tubulin), according to the manufacturer’s instruction.

Statistical analyses
All experiments adhered to the ARRIVE guidelines and followed strict randomisation. All experiments and data analysis were conducted in a blind manner using coded tags rather than actual group name. A power analysis was performed prior to the study to estimate sample-size. We hypothesized that STS or NaHS would reduce IH by 50%. Using an SD at +/- 20% for the surgery and considering a power at 0.9, we calculated that n = 12 animals/group was necessary to validate a significant effect of the STS or NaHS. Animals with pre-existing conditions (malocclusion, injury, abnormal weight) were not operated or excluded from the experiments upon discovery during dissection (kidney disease). A few animals died during surgery or did not recover from surgery and had to be euthanized before the end of the experiment. All experiments were analysed using GraphPad Prism 9. Normal distribution of the data was assessed using Shapiro-Wilk test and Kolmogorov-Smirnov test. All data had a normal distribution. One or 2-ways ANOVA were performed followed by multiple comparisons using post-hoc t-tests with the appropriate correction for multiple comparisons.
Ethics statement
Human great saphenous veins were obtained from donors who underwent lower limb bypass surgery. Written, informed consent was obtained from all vein donors for human vein and VSMC primary cultures. The study protocols for organ collection and use were reviewed and approved by the Centre Hospitalier Universitaire Vaudois (CHUV) and the Cantonal Human Research Ethics Committee (http://www.cer-vd.ch/, no IRB number, Protocol Number 170/02), and are in accordance with the principles outlined in the Declaration of Helsinki of 1975, as revised in 1983 for the use of human tissues.

All animal experimentations were conformed to the National Research Council: Guide for the Care and Use of Laboratory Animals. All animal care, surgery, and euthanasia procedures were approved by the CHUV and the Cantonal Veterinary Office (SCAV-EXPANIM, authorisation number 3114, 3258 and 3504).

Role of funding source
The funding sources had no involvement in study design, data collection, data analyses, interpretation, or writing of report.

Results
STS limits IH development in mice after carotid artery stenosis
We first assessed whether STS protects against IH as measured 28 days after mouse carotid artery stenosis (CAS). STS treatment (4 g/L) decreased IH by about 50% in WT mice (Figure 1a), as expressed as the mean intima thickness, the ratio of intima over media thickness (I/M), or the area under the curve of intima thickness calculated over 1 mm. We further tested the safety of systemic STS treatment by looking at several blood parameters.

Figure 1. STS decrease IH formation after carotid artery stenosis in mice and in cultured human saphenous veins. a, b) WT (a) or LDLR−/− mice (b) treated or not (ctrl) with 4 g/L STS were subjected to the carotid artery stenosis surgery. VGEL staining of left carotid cross sections and morphometric measurements of intima thickness, media thickness, intima over media ratio and intima thickness AUC. Scale bar 40 µm. Data are mean±SEM of 13 (c) and 8 (b) animals per group. *p < .05, **p < .01, ***p < .001 as determined by bilateral unpaired t-test. c) Intima thickness, media thickness and intima over media thickness calculated over 1 mm. Scale bar 60 µm. Data are mean ± SEM of 12 different veins/patients. *p < .05, **p < .01, ***p < .001, as determined by repeated measures one-way ANOVA with Dunnett’s multiple comparisons.
parameters, revealing that STS had no effect on kidney (urea), liver (ASAT, ALAT) and heart (CK, CK-MB) function. STS also had no effect on blood pH and HCO3 levels and blood chemistry (Na, Ca, K) levels (supplementary Table S3). To model the hyperlipidemic state of patients with PAD, we also performed the CAS model on hypercholesterolemic LDLR−/− mice fed for 3 weeks with a cholesterol-rich diet. As expected, the LDLR−/− mice developed more IH than WT mice upon CAS, and STS treatment lowered IH by about 70% (Figure 1b). Interestingly, STS did not reduce media thickness in WT mice (p = 0.39) but significantly reduced media thickness in LDLR−/− mice (p = 0.0067; Figure 1b).

STS had no effect on media thickness in native carotids of WT and LDLR−/− mice (Figure S1 in the online supplementary files). Of note, the sodium salt H2S donor NaHS (0.5 g/L) also significantly decreased IH following carotid stenosis in WT mice (Figure S2).

STS limits IH development in a model of ex vivo human vein segment culture

Both STS (15 mM) and NaHS (100 µM) inhibited IH development in our validated model of static ex vivo human vein segment culture as measured by intima thickness and I/M ratio (Figure 1c). The polysulfide/H2S donors diallyl trisulfide (DATS), cysteine-activated H2S donor 5a and GYY4137 also prevented the development of IH in human vein segments (Figure S3).

STS is a biologically active source of sulfur

Overall, STS and “classical” H2S donors similarly inhibit IH. To measure whether STS releases detectable amounts of H2S or polysulfides, we used the SF7-AM probe and SSP4 probes, respectively. We could not detect any increase in SF7-AM or SSP4 fluorescence in presence of STS with or without VSMCs. Na2S3 was used as a positive control for the SSP4 probe and NaHS as a positive control for the SF7-AM probe (Figure S4). The biological activity of H2S is mediated by post-translational modifications of reactive cysteine residues by persulfidation, which influence protein activity. As a proxy for H2S release, we assessed global protein persulfidation by DAZ-2-Cys5.5 labelling of persulfide residues in VSMCs treated for 4 h with NaHS or STS. Both STS and NaHS similarly increased persulfidation in VSMCs (Figure 2a). STS, but not NaHS, also increased the mRNA expression of TST and SUOX (Figure 2b, c), which are key enzymes of the H2S biosynthetic pathway and sulfate oxidizing unit involved in thiosulfate metabolism. Using the SSP4 probe, we further observed higher polysulfides levels in vivo in the plasma of mice treated for 1 week with 4 g/L STS (Figure 2d). Similarly, we observed a non-significant increase in polysulfides in the liver of mice treated with STS (p = 0.15). As a positive control, mice treated with 0.5 g/L NaHS had significantly higher polysulfides levels in the liver (Figure 2e). CSE is the main enzyme responsible for endogenous H2S production in the vasculature and Cse−/− mice have been shown to develop more IH. To study the impact of STS on restenosis independently of endogenous H2S production, we generated a new Cse−/− mouse line. As expected, these mice did not express Cse (Figure 2f), nor produced H2S in the liver (Figure 2g), which is the main CSE-expressing tissue. These mice did not display any growth defect (Figure S5a), had normal systolic blood pressure (Figure S5b) and carotid and aortic arteries were similar to Cse+/+ littermates (Figure S5c). Consistent with a role as an H2S donor, STS fully rescued Cse−/− mice from increased IH in the model of carotid artery stenosis (Figure 2h).

STS blocks VSMC proliferation and migration

IH is driven by VSMC reprogramming towards a proliferating, migrating and ECM-secreting phenotype. Both STS and NaHS significantly reduced the percentage of proliferating cells (defined as PCNA positive nuclei over total nuclei) in vivo in CAS-operated carotids in WT mice (Figure 4a) and ex vivo in human vein segments (Figure 4b).
Figure 2. STS increases protein persulfidation. (a) In situ labelling of intracellular protein persulfidation assessed by DAZ-2:Cy5.5 (red), normalized to NBF-adducts fluorescence (green), in VSMCs exposed for 4 h to NaHS (100 µM) or STS (15 mM). Representative images of 5 independent experiments. Scale bar 20 μM. 
(b, c) Human TST and SUOX mRNA levels in VSMCs treated or not (Ctrl) for 24 h with NaHS (100 µM) or STS (15 mM). (d) Plasma polysulfides levels, as measured by the SSP4 probe, in mice treated 7 days with STS 4 g/L. Data are scatter plots with mean ± SEM of 4 animals per group. ***p < .001 as determined by bilateral unpaired t-test. 
(e) Polysulfides levels, as measured by the SSP4 probe in liver extracts of mice treated 7 days with STS 4 g/L or NaHS 0.5 g/L. Data are scatter plots with mean ± SEM of 5 animals per group. **p < .01 as determined by One-way ANOVA with post-hoc t-tests with Tukey's correction for multiple comparisons. 
(f) Western blot analysis of Cse, Cbs and 3-Mst in Cse−/− and Cse+/+ mice, treated or not with STS 4 g/L for 4 weeks (3 to 5 animals per group). (g) Lactate assay to measure Cse-mediated H2S production in Cse−/− and Cse+/+ mice. Data are representative of 4 animals per group. (h) Intima thickness, media thickness, intima over media ratio and intima thickness AUC of CAS operated mice measured 28 days after surgery in Cse−/− versus Cse+/+ mice treated or not (Cse−/− Ctrl) with 4 g/L STS (Cse−/− STS). Scale bar 50 μm. Data are scatter plots with mean ± SEM of 8 to 10 animals per group. *p < .05, **p < .01, as determined by one-way ANOVA with post-hoc t-tests with Tukey’s correction for multiple comparisons.
Figure 3. STS decreases apoptosis and matrix deposition in human vein segments. Human vein segment at day 0 (D0) or after 7 days of static culture with or without (D7) 15 mM STS or 100 µM NaHS. (a) Representative Herovici staining of 5 different human vein segments. Mature collagen I is stained pink; new collagen III is stained blue; cytoplasm is counterstained yellow; nuclei are stained blue to black. Scale bar=80 µm. (b) Left panels: Representative P4HA1 staining. Scale bar=50 µm. Right panel: Quantitative assessment of P4HA1 staining. Data are scatter plots of 5 different veins with mean ± SEM. ***p < .01 as determined by paired repeated measures one-way ANOVA with Dunnett’s multiple comparisons. (c) Left panels: Representative TUNEL staining in human vein segments. Right panel: Apoptosis is expressed as TUNEL positive (green) over DAPI positive nuclei. Scale bar= 50 µm. Data are...
In vitro, STS dose-dependently decreased primary human VSMC proliferation as assessed by BrdU incorporation assay (Figure 5a). Of Note, NaHS as well as DATS, H2S donor 5Å and GYY4137, also decreased VSMC proliferation (Figure S8). STS and NaHS also decreased VSMC migration in a wound healing assay, in absence (Figure 5b), or in presence of the mitosis inhibitor mitomycin C (Figure S9). Further evaluation of cell morphology during the wound healing revealed that STS and NaHS-treated cells lost the typical elongated shape of VSMCs, as measured through the area, Feret diameter and circularity of the cells (Figure 5c). Of note, 15 mM STS did not induce VMSC apoptosis after 48 h, while 40 mM STS increased apoptosis levels to 5%. 80 mM STS for 48 h raised apoptosis levels to 10% (Figure S10).

STS does not significantly impact VSMC metabolism

We previously showed that H2S inhibits the mitochondrial metabolism while increasing glycolysis in endothelial cells.43 To assess the impact of STS on VSMC metabolism, Seahorse experiments were performed on VSMCs treated for 4 or 24 h with STS. Surprisingly, STS did not inhibit mitochondrial respiration in a mitochondrial stress test after 4 h of pre-treatment, while NaHS had a slight effect on basal respiration and ATP production (Figure S11a). After 24 h of treatment, both STS and NaHS increased respiration mildly (Figure S11b). We also performed a glycolysis stress test to evaluate the metabolic flexibility of VSMCs (Figure S11c). After 24 h of pre-treatment, neither STS nor NaHS impacted glycolysis. Of note, VSMCs had a null glycolytic reserve, i.e. glycolysis did not increase upon inhibition of mitochondrial respiration with oligomycin. Further analysis of oxphos proteins by western blot showed no effect of a 24 h STS treatment on key mitochondrial enzymes (Figure S12). Overall, STS effect on mitochondrial respiration and glycolysis cannot explain the reduced proliferation and migration observed.

STS interferes with microtubules organization

Given the impact of STS on cell morphology, we examined the effect of STS on the cytoskeleton. α-tubulin levels were increased in the carotid wall of CAS-operated mice, which were reduced by STS, as demonstrated by immunohistochemistry (Figure 6a). α-tubulin levels were also decreased in the native aorta of mice treated with STS for 7 days (Figure 6b). On the other hand, STS did not impact tubulin staining in native carotids of WT and LDLR−/− mice (Figure S13a). STS treatment also had no effect on tubulin levels in the liver and kidney (Figure S13b). In ex vivo vein segments, total α-tubulin levels were decreased after 7 days of STS or NaHS treatment (Figure 6c, d). Looking further at α-tubulin by immunofluorescent staining showed a loss in microtubule in VSMCs treated with STS or NaHS for 8 h (Figure 6 e, f). To study the effect of H2S on microtubule formation, an in vitro tubulin polymerization assay was performed in presence of 15 mM STS, 100 µM NaHS or 10 µM Nocodazole, an inhibitor of microtubule assembly. As expected, Nocodazole slowed down microtubule assembly as compared to the control. Surprisingly, both NaHS and STS fully blocked microtubule assembly in this assay (Figure 6g). Further studies of the cell cycle in VSMCs revealed that 48 h of treatment with STS or Nocodazole resulted in accumulation of cells in G2/M phase (Figure 6h).

Discussion

Despite decades of research and the advent of drug-eluting stents (DES) and drug-coated balloons (DCB), intimal hyperplasia (IH) remains one of the major limitations in the long-term success of revascularization. All current strategies based on the use of DES and DCB limit VSMC proliferation and IH, but they also affect re-endothelisation, limiting their long-term efficacy and prolonging the need for anti-thrombotic. Moreover, recent controversies regarding the long-term safety of paclitaxel-releasing devices6–13 advocate for the development of new therapies to limit IH. These new strategies should focus on inhibiting VSMC proliferation while promoting endothelium recovery. In that regard, the gasotransmitter H2S possesses interesting properties. Here, we demonstrate that exogenous sulfur supplementation in the form of STS limits IH development in vivo following mouse carotid artery stenosis. Furthermore, STS reduced apoptosis, vessel remodelling and collagen deposition, along with IH development in our ex vivo model of IH in human vein segments. We propose that STS limits IH by interfering with the microtubule dynamics, thus VSMC proliferation and migration.

An ever increasing number of studies document the protective effects of H2S against cardiovascular diseases,44 including studies showing that H2S reduces IH in preclinical models.39–21,45 The administration of H2S in those studies relies on soluble sulfide salts such as NaHS with narrow therapeutic range due to fast and uncontrolled release. Thiolsulfate is an intermediate of

scatter plots of 5 to 6 different veins with mean ± SEM. *p < .05, **p < .001 as determined by mixed model analysis with Dunnett’s multiple comparisons. (d) Representative western blot of Bax and Bcl2 over total protein and quantitative assessment of 7 different human veins. Data are scatter plots with mean ± SEM. *p < .05 as determined by repeated measures one-way ANOVA with Dunnett’s multiple comparisons (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.).
sulfur metabolism shown to release H\(_2\)S in vivo through non-enzymatic and enzymatic mechanisms.\(^{25,26,46,47}\) Importantly, STS is clinically approved and safe in gram quantities in humans. Although STS yields no detectable H\(_2\)S or polysulfide \textit{in vitro}, we observed increased circulating and liver levels of polysulfides in mice, as well as increased protein persulfidation in VSMCs. We further showed that STS treatment rescues Cse\(^{-/-}\) with impaired endogenous H\(_2\)S production from increased IH. This is in line with a previous study.

**Figure 4.** STS inhibits cell proliferation \textit{in vivo} in mouse carotids and \textit{ex-vivo} in human vein segments. PCNA immunostaining on CAS operated carotids in WT mice (a) treated or not (Ctrl) with STS 4 g/L or NaHS 0.5g/L for 28 days, and human vein segments (b) incubated or not (Ctrl) with 15 mM STS or 100 \(\mu\)M NaHS for 7 days. Proliferation is expressed as the ratio of PCNA positive (brown) nuclei over total number of nuclei. Data are scatter plots with mean±SEM. (a) Scale bar 20 \(\mu\)m. *\(p<.05\), **\(p<.01\), ***\(p<.001\) as determined from 8 to 12 animals per group by one-way ANOVA with Dunnett’s multiple comparisons. (b) Scale bar 50 \(\mu\)m **\(p<.01\), as determined from 5 to 7 different veins by mixed model analysis and Dunnett’s multiple comparisons.
Figure 5. STS inhibits VSMC proliferation and migration in vitro. (a) VSMC proliferation (BrdU incorporation) in cells treated or not (Ctrl) for 24 h with 3 or 15 mM STS. Data are % of BrdU positive nuclei (pink) over DAPI positive nuclei. Scale bar: 25 \( \mu m \). Data shown as mean ± SEM of 6 different experiments. * \( p < .05 \) as determined by repeated measures one-way ANOVA with Dunnett’s multiple comparisons tests. (b) VSMC migration in cells treated or not (Ctrl) with 3 or 15 mM STS, as assessed by wound healing.
showing that NaHS rescues increased IH in a model of carotid ligation in another Cse−/− mouse line. Overall, STS has protective effects against IH similar to the H₂S salt NaHS and several other “classical” H₂S donors, but holds much higher translational potential.

Mechanistically, we first observed that STS reduces cell apoptosis and matrix deposition in our ex vivo model of human vein segments. This anti-apoptotic effect of STS and NaHS is in line with known anti-apoptotic effects of H₂S. STS also reduces IH in vivo following carotid artery stenosis. In this model, matrix deposition plays little role in the formation of IH, which relies mostly on VSMC proliferation. Therefore, although ECM and especially collagen deposition are major features of IH in humans, reduced apoptosis and matrix deposition is not sufficient to fully explain the protection afforded by STS in carotids in vivo.

STS, similarly to the H₂S donor NaHS, inhibits VMSC proliferation in the context of IH in vivo in mouse stenotic carotids, ex vivo in human vein segments, and in vitro in primary human VMSCs. These findings are in line with previous studies demonstrating that “classical” H₂S donors decrease VSMCs proliferation in pre-clinical models. In mouse VMSC, exogenous H₂S has been proposed to promote cell cycle arrest, and regulate the Mitogen-activated protein kinases (MAPK) pathway and Insulin-like Growth Factor (IGF-1) response. Regarding mouse VSMC migration, H₂S may limit αβ1-integrin and matrix metalloproteinase-2 (MMP2) expression, preventing migration and ECMs degradation. In this study, we further document that STS and NaHS disrupt the formation of microtubules in human VMSCs in vitro. Our findings are in line with previous studies showing that Diallyl trisulfide, a polysulfide donor, inhibits microtubule polymerization to block human colon cancer cell proliferation. NaHS also depolymerizes microtubules within Aspergillus nidulans biofilms.

The α/β tubulin dimer has 20 highly conserved cysteine residues, which have been shown to regulate microtubule formation and dynamics. In particular, thiol–disulfide exchanges in intra-chain disulfide bonds have been proposed to play a key role in microtubule assembly. Several high throughput studies of post-translational modification of protein cysteinyl thiols (–SH) to persulfides (–SSH) demonstrated that cysteine residues in α- and β-tubulin are persulfidated in response to H₂S donors in various cell types. Given the prominent role of cytoskeleton dynamics and remodelling during mitosis and cell migration, we propose that STS/H₂S-driven microtubule depolymerisation, secondary to cysteine persulfidation, contributes to cell cycle arrest and reduces migration in VMSC.

Our findings suggest that STS holds strong translational potential to limit restenosis following vascular surgeries. The dosage of STS used in this study is comparable to previous experimental studies using oral administration at 0.5 to 2 g/Kg/day, and we did not observe any adverse effect of the 30-days treatment with STS on blood chemistry and plasmatic markers of kidney, liver and heart function. In humans, 12.5 and 25 g of STS have been infused without adverse effects and short-term treatment with i.v. STS is safely used in patients for the treatment of calciphylaxis. Of note, the pathophysiology of calciphylaxis, also known as calcific uremic arteriopathy (CUA), is caused by oxidative stress and inflammation, which promote endothelial dysfunction, leading to medial remodelling, inflammation, fibrosis and VSMC apoptosis and differentiation into bone forming osteoblast-like cells. Although the main effect of STS on CUA is via formation of highly soluble calcium thiosulfate complexes, our data supports the use of STS in the treatment of calciphylaxis. Plus, STS infusions have been shown to increase distal cutaneous blood flow, which could be beneficial in the context of vascular occlusive disease.

Here, we propose that STS treatment results in persulfidation of cysteine residues in the tubulin proteins, which lead to microtubule depolymerisation. However, further studies are required to test this hypothesis and demonstrate the STS-induced persulfidation of tubulin cysteine residues. In addition, although we show in vitro that H₂S directly affect microtubule formation in a cell-free environment, other proteins involved in the microtubules dynamics in vivo may also be modified by H₂S, and contribute to the effect of STS on microtubule polymerisation and cell proliferation. This effect on microtubules could lead to side effects similar to microtubule targeting agents such as nocodazole or colchicine and paclitaxel, which are widely used in the treatment of various cancers. However, unlike chemotherapeutic agents, the effect of STS/H₂S should be reversible, which should reduce side effects. That said, additional experiments in larger animals are required to better assess haematological, gastrointestinal and neurological toxicities of long-term treatment with STS. In this study, STS was administered in the water bottle. However, given the low and variable bioavailability of oral STS,

assay, expressed as the percentage of wound closure after 10 h. Scale bar: 100 µm. Data are scatter plots with mean ± SEM of 5 independent experiments in duplicates. ***p < .001 as determined by repeated measures one-way ANOVA with Dunnett’s multiple comparisons. (c) Bright field images of VMSC morphology in cells exposed or not (Ctrl) to 15 mM STS or 100 µm NaHS, as measured as cell perimeter, cell area, Feret diameter and circularity index assessed during wound healing assay. Data are violin plots with median and quartiles (dotted lines) of 5 independent experiments. ***p < .001 as determined by one-way ANOVA with Dunnett’s post-hoc test. Scale bar: 80 µm. Pink and blue insets are 3-fold magnifications of outlined areas.
Figure 6. STS inhibits microtubule polymerization in VSMC. (a) α-tubulin immunolabelling in carotids of native (D0) or CAS-operated mice treated or not (Ctrl) with STS 4 g/L. L=Lumen; M=Media; IH=Intimal Hyperplasia. Images are representative of 5 to 8 mice per group. Scale bar 20 µm (b) WB analysis of α-tubulin over total protein in aortas of mice treated or not (Ctrl) with STS 4 g/L for 7 days. Data are scatter plots of 7 mice per groups with mean ± SEM with **p < .01, as determined by one-way ANOVA with Tukey’s multiple comparisons tests. (c) α-tubulin immunolabelling in human vein segments kept or not (D0) in culture in presence or not (Ctrl) of 15 mM STS for 7 days. Scale bar 40 µm. L=Lumen; M=Media. Images are representative of 5 different veins. (d) WB analysis of tubulin over total protein in human vein segments kept or not (D0) in culture in presence or not (Ctrl) of 15 mM STS or 100 µM NaHS for 7 days. *p < .05, **p < .01, ***p < .001, as determined by repeated measures one-way ANOVA from 7 different veins with Dunnett’s multiple comparisons tests. (e) α-tubulin immunofluorescent staining in VSMC exposed or not to 15 mM STS or 100 µM NaHS for 8 h. Images are representative of 5 independent experiments. Bar scale 10 µm. (f) Quantitative assessment of microtubule filaments immunostaining per cell. Data are representative of 3 independent experiments, 3 to 4 images per experiment per condition. ***p < .001 as determined by one-way ANOVA with Tukey’s multiple comparisons tests. (g) In vitro tubulin polymerization assay in presence or not (Ctrl) of 15 mM STS, 100 µM NaHS or 10 µM Nocodazole. Data are mean ± SEM of 3 independent experiments. (h) Flow cytometry analysis of cell cycle (DNA content) using DAPI-stained VSMC treated or not (Ctrl) for 48 h with 15 mM STS or 10 nm Nocodazole. Upper panel: representative histograms; lower panel: table with mean ± SD of 5 independent experiments. *p < .05, **p < .01 as determined by one-way ANOVA with Dunnett’s multiple comparisons tests.
only intravenous STS should be prescribed. Moving forward, further studies in large animals are required to validate the therapeutical potential and setup the i.v. dose of STS required in a model of restenosis. Case reports and case series suggest that i.v. STS administration is safe, even for relatively long periods of time. However, randomised controlled trials testing long-term administration of STS are lacking, and the long-term safety and effects of STS administration should be further explored.

In summary, under the conditions of these experiments, STS, a FDA-approved compound, limits IH development in vivo in a model of arterial restenosis and ex vivo model in human veins. STS most likely acts by increasing H₂S bioavailability, which inhibits cell apoptosis and matrix deposition, as well as VSMC proliferation and migration via microtubules depolymerisation.

Contributors
FA, AL and SD designed the study. FA, DM, MMA, ML and SU performed the experiments. FA, DM, MMA, ML and SD analysed the data. FA, DM, MMA, AL and SD wrote the manuscript. FA, AL and SD revised the manuscript.

Data sharing statement
The data that support the findings of this study are available from the corresponding author, Florent Allagnat, upon request.

Declaration of interests
The authors declare no competing interests.

Acknowledgments
We thank the mouse pathology facility for their services in histology (https://www.unil.ch/mpf).

Supplementary materials
Supplementary material associated with this article can be found in the online version at doi:10.1016/j.ebiom.2022.101954.

References
1 Enzo LH, Fukaya E, Mohler ER, Xie D, Sha D, Berger JS. Peripheral arterial disease, prevalence and cumulative risk factor profile analysis. *Eur J Prev Cardiol*. 2014;21(6):704–711.
2 Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. *Lancet*. 2013;381(9862):1215–1225.
3 Song P, Rudan D, Zhu Y, et al. Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: an updated systematic review and analysis. *Lancet Glob Health*. 2019;7(8):e1020–e1030.
4 Bjorck M, Earnshaw JJ, Acosta S, et al. Editor’s choice - European Society for Vascular Surgery (ESVS) 2020 clinical practice guidelines on the management of acute limb ischaemia. *Eur J Vasc Endovasc Surg*. 2020;59(2):173–178.
5 Jukema JW, Verschueren JJ, Ahmed TA, Quax PH. Restenosis after PCI. Part 1: pathophysiology and risk factors. *Nat Rev Cardiol*. 2011;8(9):51–62.
6 Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Karnabatidis D. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. *J Am Heart Assoc*. 2018;7(24):e011245.
7 Roche-Singh KJ, Duval S, Jaff MR, et al. Mortality and paclitaxel-coated devices: an individual patient data meta-analysis. *Circulation*. 2020;141(13):1859–1869.
8 Roos R, Chakraborty A, Zhao Y. US Food and Drug Administration perspective on "mortality and paclitaxel-coated devices: an individual patient data meta-analysis". *Circulation*. 2020;141(13):1870–1871.
9 Dinh K, Gomes ML, Thomas SD, et al. Mortality after paclitaxel-coated device use in patients with chronic limb-threatening ischaemia: a systematic review and meta-analysis of randomized controlled trials. *J Endovasc Ther*. 2020;27(2):175–185.
10 Ippena J, Huizing E, Schreve MA, de Vries JPM, Unlu C. Editor’s choice - drug-coated balloon angioplasty vs. standard percutaneous transluminal angioplasty in below the knee peripheral arterial disease: a systematic review and meta-analysis. *Eur J Vasc Endovasc Surg*. 2020;59(2):265–275.
11 Katsanos K, Spiliopoulos S, Kitrou P, Krokidis M, Pazzaskevopoulou I, Karnabatidis D. Risk of death and amputation with use of paclitaxel-coated balloons in the infrapopliteal arteries for treatment of critical limb ischaemia: a systematic review and meta-analysis of randomized controlled trials. *J Vasc Interv Radiol*. 2020;31(2):202–212.
12 Nordanstig J, James S, Andersson M, et al. Mortality with paclitaxel-coated devices in peripheral artery disease. *N Engl J Med*. 2020;382(26):2538–2546.
13 Secemsky EA, Kundi H, Weinberg I, et al. Association of survival with femoropopliteal artery revascularization with drug-coated devices. *JAMA Cardiol*. 2019;4(4):332–340.
14 Davies MG, Hagen PO. Reprinted article “pathophysiology of vein graft failure: a review”. *Eur J Vasc Endovasc Surg*. 2001;42 Suppl 1: S9–S29.
15 Zhang L, Wang Y, Li Y, et al. Hydrogen sulfide (H₂S)-releasing compounds: therapeutic potential in cardiovascular diseases. *Front Pharmacol*. 2018;9:1066.
16 Yang G, Wu L, Bryan S, Klaper N, Mani S, Wang R. Cystathionine gamma-lyase deficient mice: role of hydrogen sulfide in smooth muscle cells. *Cardiovasc Res*. 2019;110(4):487–495.
17 Islam KN, Polhemus DJ, Donnarumma E, Brewster LP, Lefer DJ. Hydrogen sulfide levels and nuclear factor-erythroid 2-related factor 2 (NRF2) activity are attenuated in the setting of critical limb ischemia (CLI). *J Am Heart Assoc*. 2015;4(5).
18 Longchamp A, MacArthur MR, Trocha K, et al. Plasma hydrogen sulfide production capacity is positively associated with post-operative survival in patients undergoing surgical. *Revascularization*. 2021;2021.02.16.21235804.
19 Meng QH, Yang G, Yang W, Jiang B, Wu L, Wang R. Protective effect of hydrogen sulfide on balloon injury-induced neointima hyperplasia in rat carotid arteries. *Am J Pathol*. 2007;170(4):1406–1414.
20 Ma B, Liang G, Zhang F, Chen Y, Zhang H. Effect of hydrogen sulfide on restenosis of peripheral arteries after angioplasty. *Mol Med Rep*. 2012;5(6):1497–1502.
21 Yang G, Li H, Tang C, et al. Increased neointimal formation in cystathionine gamma-lyase deficient mice: role of hydrogen sulfide in alpha5beta1-integrin and matrix metalloproteinase-2 expression in smooth muscle cells. *J Mol Cell Cardiol*. 2012;52(3):677–688.
22 Longchamp A, Kaur K, Macabrey D, et al. Hydrogen sulfide-releasing peptide hydrogel limits the development of intimal hyperplasia in human vein segments. *Acta Biomater*. 2019.
23 Befarta VS, Brittain M, Chan A, et al. Sodium nitrite and sodium thiosulfate are effective against acute cyanide poisoning when administered by intramuscular injection. *Ann Emerg Med*. 2017;69(6):718–725.
24 Nigwekar SU, Thadhani R, Brandenburg VM. Cystathionylx. *N Engl J Med*. 2018;378(18):1704–1714.
Articles

25 Olson KR, Deleon ER, Gao Y, et al. Thiosulfate: a readily accessible source of hydrogen sulfide in oxygen sensing. *Am J Physiol Regul Integr Comp Physiol.* 2013;305(6):R1592–R605.

26 Snijder PM, Frenay AR, de Boer RA, et al. Exogenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angiotensin II-induced hypertensive heart disease in rats. *Br J Pharmacol.* 2015;172(2):1494–1504.

27 Ishibashi S, Brown MS, Goldstein JI, Gerard RD, Hammer RE, Hertz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. *J Clin Invest.* 1993;92(2):885–893.

28 Tao M, Mauro CR, Yu P, et al. A simplified murine intimal hyperplasia model founded on a focal carotid stenosis. *Am J Pathol.* 2017;182(3):277–287.

29 Allagat F, Dubuis C, Lambelet M, et al. Connexin17 reduces smooth muscle cell proliferation and intimal hyperplasia in a mouse model of carotid artery ligation. *Cardiovasc Res.* 2017;111(7):837–846.

30 Longchamp A, Alonso F, Dubuis C, et al. The use of external mesh reinforcement to reduce intimal hyperplasia and preserve the structure of human saphenous veins. *Biomaterials.* 2014;35(20):2588–2599.

31 Lin VS, Lippert AR, Chang CJ. Cell-trappable fluorescent probes for endogenous hydrogen sulfide signaling and imaging H₂O₂-dependent H₂S production. *Proc Natl Acad Sci U S A.* 2015;112(8):2731–2736.

32 Zivanovic J, Kouroussis E, Kohl JB, et al. Selective persulfide detection reveals evolutionarily conserved antiaging effects of S-sulfhydration. *Cell Metab.* 2019;30(6):1152–1170.e11.

33 Teuscher AC, Statzer C, Fantasó S, Bordoli MR, Zukunft S. A selective and sensitive method for endogenous hydrogen sulfide signaling and imaging H₂O₂-dependent H₂S production. *Proc Natl Acad Sci U S A.* 2010;107(7):2731–2736.

34 Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. *Matrix Biol.* 2002;21(1):35–54.

35 Longchamp A, Mirabella T, Arduini A, et al. Amino acid restriction triggers angiotension via GCN2/ATF4 regulation of VEGF and H₂S production. *Cell Death Dis.* 2015;6(11):e1910.

36 Szabo C. A timeline of hydrogen sulfide (H₂S) research: from environmental toxin to biological mediator. *Biochem Pharmacol.* 2018;149:143–152.

37 Yuan S, Yurdagul A, Peretik JM, et al. Cystathionine gamma-lyase drives intimal hyperplasia in mouse models of hypertension. *J Am Heart Assoc.* 2020;9(22) e016391.

38 Marzani E, Yarnada M, Ida T, et al. Thiosulfate mediates cytoprotective effects of hydrogen sulfide against neuronal ischemia. *J Am Heart Assoc.* 2015;4(11).

39 Lee M, McGeer EG, McGeer PL. Sodium thiosulfate attenuates glial-mediated neuroinflammation in degenerative neurological diseases. *J Neuroinflammation.* 2016;13:32.

40 Farh A, Koledgie FD, Hwang JY, et al. Extracellular matrix changes in stented human coronary arteries. *Circulation.* 2004;110(8):940–947.

41 Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. *Matrix Biol.* 2009;28(2):166–183.

42 Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. *Matrix Biol.* 2009;28(2):166–183.

43 Longchamp A, Mirabella T, Arduini A, et al. Amino acid restriction triggers angiotension via GCN2/ATF4 regulation of VEGF and H₂S production. *Cell Death Dis.* 2015;6(11):e1910.

44 Szabo C. A timeline of hydrogen sulfide (H₂S) research: from environmental toxin to biological mediator. *Biochem Pharmacol.* 2018;149:143–152.

45 Kip P, Tao M, Trocha RM, et al. Periprocedural hydrogen sulfide therapy improves vascular remodeling and attenuates vein graft disease. *J Am Heart Assoc.* 2020;9(22) e016391.

46 Serur D. Long-term intravenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angio genesis via GCN2/ATF4 regulation of VEGF and H₂S production. *Cell Death Dis.* 2015;6(11):e1910.

47 Lee M, McGeer EG, McGeer PL. Sodium thiosulfate attenuates glial-mediated neuroinflammation in degenerative neurological diseases. *J Neuroinflammation.* 2016;13:32.

48 Farh A, Koledgie FD, Hwang JY, et al. Extracellular matrix changes in stented human coronary arteries. *Circulation.* 2004;110(8):940–947.

49 Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. *Matrix Biol.* 2009;28(2):166–183.

50 Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. *Matrix Biol.* 2009;28(2):166–183.

51 Shuang T, Fu M, Yang C, Wu L, Wang R. The interaction of IGF-1/IGF-1R and hydrogen sulfide on the proliferation of mouse primary vascular smooth muscle cells. *Biochem Pharmacol.* 2018;149:143–152.

52 Shuang T, Fu M, Yang C, Wu L, Wang R. The interaction of IGF-1/IGF-1R and hydrogen sulfide on the proliferation of mouse primary vascular smooth muscle cells. *Biochem Pharmacol.* 2018;149:143–152.

53 Shukla N, Osmani AH, Osmani SA. Microtubules are reversibly depolymerized in response to changing gaseous microenvironments within Aspergillus nidulans biofilms. *Mol Biol Cell.* 2017;28(9):614–644.

54 Britto PJ, Knupling L, McPhie P, Wolff J. Thiol-disulphide interchange in tubulin: kinetics and the effect on polymerization. *Biochim J.* 2005;389(Pt 2):549–558.

55 Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. *Matrix Biol.* 2009;28(2):166–183.

56 Serur D. Long-term intravenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angio genesis via GCN2/ATF4 regulation of VEGF and H₂S production. *Cell Death Dis.* 2015;6(11):e1910.

57 Myllyharju J. Prolyl 4-hydroxylases, the key enzymes of collagen biosynthesis. *Matrix Biol.* 2009;28(2):166–183.

58 Serur D. Long-term intravenous administration of thiosulfate, a donor of hydrogen sulfide, attenuates angio genesis via GCN2/ATF4 regulation of VEGF and H₂S production. *Cell Death Dis.* 2015;6(11):e1910.

59 Brucculeri M, Cheigh J, Bauer G, Serur D. Long-term intravenous sodium thiosulfate in the treatment of a patient with calciphylaxis. *Semin Dial.* 2005;18(5):431–434.

60 Schlieper G, Brandenburg V, Ketteler M, Froeg S. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. *Nat Rev Nephrol.* 2009;5(9):539–543.